Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia

Blood

Volumn 121, Issue 19, 2013, Pages 3843-3854

  Teramo, Antonella ^a,b   Gattazzo, Cristina ^a,b   Passeri, Francesca ^a,b   Lico, Albana ^a   Tasca, Giulia ^a   Cabrelle, Anna ^b   Martini, Veronica ^a,b   Frezzato, Federica ^a,b   Trimarco, Valentina ^a,b   Ave, Elisa ^a,b   Boscaro, Elisa ^a   Piazza, Francesco ^a,b   Facco, Monica ^a,b   Trentin, Livio ^a,b   Semenzato, Gianpietro ^a,b   Zambello, Renato ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; JANUS KINASE; PROTEIN MCL 1; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; SOCS3 PROTEIN, HUMAN; STAT PROTEIN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; MALE; MIDDLE AGED; MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING; CELL CULTURE; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AGED; CELLS, CULTURED; FEMALE; HUMANS; JANUS KINASES; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MLCS; MLOWN;

EID: 84880475097     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-441378     Document Type: Article

References (43)

1. Baesso I, Pavan L, Boscaro E, et al. T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. Leuk Res. 2007;31(3):371-377.
2. Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica. 2009;94(10):1341-1345.
3. Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist. 2006; 11(3):263-273.
4. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362.
5. Schade AE, Wlodarski MW, Maciejewski JP. Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. Cell Cycle. 2006;5(22): 2571-2574.
6. Rawlings JS, Rosler KM, Harrison DA. The JAK/ STAT signaling pathway. J Cell Sci. 2004; 117(Pt 8):1281-1283.
7. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15: 797-819.
8. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-236.
9. Rabe BCA, Chalaris A, May U, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111(3):1021-1028.
10. Yamamoto K, Rose-John S. Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther. 2012;91(4): 574-576.
11. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41-51.
12. Campbell CL, Jiang Z, Savarese DM, Savarese TM. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol. 2001;158(1):25-32.
13. Li L, Shaw PE. Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem. 2002;277(20): 17397-17405.
14. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005; 42(6):1329-1338.
15. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95(12):3765-3770.
16. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000;19(21):2496-2504.
17. Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001; 15(5):787-793.
18. Cooney RN. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock. 2002;17(2):83-90.
19. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol. 2003;4(12):1169-1176.
20. Niemand C, Nimmesgern A, Haan S, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol. 2003;170(6):3263-3272.
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1-20.
22. Croker BA, Krebs DL, Zhang JG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003;4(6):540-545.
23. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem. 2000;275(17):12848-12856.
24. Yu CR, Mahdi RM, Ebong S, Vistica BP, Gery I, Egwuagu CE. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J Biol Chem. 2003;278(32):29752-29759.
25. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20): 1905-1913.
26. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048-3057.
27. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89(1):256-260.
28. Zambello R, Trentin L, Facco M, et al. Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD31 granular lymphocytes. Cancer Res. 1995;55(24):6140-6145.
29. Zambello R, Facco M, Trentin L, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997;89(1):201-211.
30. Haider AS, Peters SB, Kaporis H, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. 2006;126(4):869-881.
31. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821-9826.
32. Niwa Y, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24(42):6406-6417.
33. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007;132(1):384-396.
34. Cho-Vega JH, Rassidakis GZ, Amin HM, et al. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. Leukemia. 2004; 18(11):1872-1878.
35. Weber A, Hengge UR, Bardenheuer W, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005;24(44):6699-6708.
36. He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 2003;100(24): 14133-14138.
37. To KF, Chan MW, Leung WK, et al. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer. 2004;91(7): 1335-1341.
38. Zambello R, Berno T, Cannas G, et al. Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood. 2005; 106(12):3926-3931.
39. Shvidel L, Duksin C, Tzimanis A, et al. Cytokine release by activated T-cells in large granular lymphocytic leukemia associated with autoimmune disorders. Hematol J. 2002;3(1):32-37.
40. Gattazzo C, Teramo A, Miorin M, et al. Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. Haematologica. 2010;95(10): 1722-1729.
41. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood. 2008;112(3): 770-781.
42. Pilati C, Amessou M, Bihl MP, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208(7): 1359-1366.
43. Clemente MJ, Wlodarski MW, Makishima H, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011; 118(16):4384-4393.